210 related articles for article (PubMed ID: 24366883)
1. CRR9/CLPTM1L regulates cell survival signaling and is required for Ras transformation and lung tumorigenesis.
James MA; Vikis HG; Tate E; Rymaszewski AL; You M
Cancer Res; 2014 Feb; 74(4):1116-27. PubMed ID: 24366883
[TBL] [Abstract][Full Text] [Related]
2. Functional characterization of CLPTM1L as a lung cancer risk candidate gene in the 5p15.33 locus.
James MA; Wen W; Wang Y; Byers LA; Heymach JV; Coombes KR; Girard L; Minna J; You M
PLoS One; 2012; 7(6):e36116. PubMed ID: 22675468
[TBL] [Abstract][Full Text] [Related]
3. Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling.
Puskás LG; Mán I; Szebeni G; Tiszlavicz L; Tsai S; James MA
Mol Cancer Ther; 2016 May; 15(5):985-97. PubMed ID: 26939707
[TBL] [Abstract][Full Text] [Related]
4. CLPTM1L induces estrogen receptor β signaling-mediated radioresistance in non-small cell lung cancer cells.
Li H; Che J; Jiang M; Cui M; Feng G; Dong J; Zhang S; Lu L; Liu W; Fan S
Cell Commun Signal; 2020 Sep; 18(1):152. PubMed ID: 32943060
[TBL] [Abstract][Full Text] [Related]
5. Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21.
Hatley ME; Patrick DM; Garcia MR; Richardson JA; Bassel-Duby R; van Rooij E; Olson EN
Cancer Cell; 2010 Sep; 18(3):282-93. PubMed ID: 20832755
[TBL] [Abstract][Full Text] [Related]
6. Kruppel-like factor 5 is not required for K-RasG12D lung tumorigenesis, but represses ABCG2 expression and is associated with better disease-specific survival.
Meyer SE; Hasenstein JR; Baktula A; Velu CS; Xu Y; Wan H; Whitsett JA; Gilks CB; Grimes HL
Am J Pathol; 2010 Sep; 177(3):1503-13. PubMed ID: 20639455
[TBL] [Abstract][Full Text] [Related]
7. The Rac1 splice form Rac1b promotes K-ras-induced lung tumorigenesis.
Zhou C; Licciulli S; Avila JL; Cho M; Troutman S; Jiang P; Kossenkov AV; Showe LC; Liu Q; Vachani A; Albelda SM; Kissil JL
Oncogene; 2013 Feb; 32(7):903-9. PubMed ID: 22430205
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of CLPTM1L expression and its effects on migration and invasion of human lung cancer cells.
Ni Z; Chen Q; Lai Y; Wang Z; Sun L; Luo X; Wang X
Cancer Biomark; 2016; 16(3):445-52. PubMed ID: 27062701
[TBL] [Abstract][Full Text] [Related]
9. [CRAF, a key player in lung adenocarcinomas induced by K-Ras oncogene].
Francoz S; Dubus P
Med Sci (Paris); 2011 Oct; 27(10):820-2. PubMed ID: 22027418
[No Abstract] [Full Text] [Related]
10. The associations of TERT-CLPTM1L variants and TERT mRNA expression with the prognosis of early stage non-small cell lung cancer.
Chen Z; Wang J; Bai Y; Wang S; Yin X; Xiang J; Li X; He M; Zhang X; Wu T; Xu P; Guo H
Cancer Gene Ther; 2017 Jan; 24(1):20-27. PubMed ID: 27982019
[TBL] [Abstract][Full Text] [Related]
11. EGFR, ErbB2 and Ras but not Src suppress RhoB expression while ectopic expression of RhoB antagonizes oncogene-mediated transformation.
Jiang K; Delarue FL; Sebti SM
Oncogene; 2004 Feb; 23(5):1136-45. PubMed ID: 14647415
[TBL] [Abstract][Full Text] [Related]
12. The TERT-CLPTM1L lung cancer susceptibility variant associates with higher DNA adduct formation in the lung.
Zienolddiny S; Skaug V; Landvik NE; Ryberg D; Phillips DH; Houlston R; Haugen A
Carcinogenesis; 2009 Aug; 30(8):1368-71. PubMed ID: 19465454
[TBL] [Abstract][Full Text] [Related]
13. Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations.
Konstantinidou G; Bey EA; Rabellino A; Schuster K; Maira MS; Gazdar AF; Amici A; Boothman DA; Scaglioni PP
Cancer Res; 2009 Oct; 69(19):7644-52. PubMed ID: 19789349
[TBL] [Abstract][Full Text] [Related]
14. CLPTM1L promotes growth and enhances aneuploidy in pancreatic cancer cells.
Jia J; Bosley AD; Thompson A; Hoskins JW; Cheuk A; Collins I; Parikh H; Xiao Z; Ylaya K; Dzyadyk M; Cozen W; Hernandez BY; Lynch CF; Loncarek J; Altekruse SF; Zhang L; Westlake CJ; Factor VM; Thorgeirsson S; Bamlet WR; Hewitt SM; Petersen GM; Andresson T; Amundadottir LT
Cancer Res; 2014 May; 74(10):2785-95. PubMed ID: 24648346
[TBL] [Abstract][Full Text] [Related]
15. Genetic polymorphisms of TERT and CLPTM1L and risk of lung cancer--a case-control study in a Chinese population.
Myneni AA; Chang SC; Niu R; Liu L; Ochs-Balcom HM; Li Y; Zhang C; Zhao B; Shi J; Han X; Li J; Su J; Cai L; Yu S; Zhang ZF; Mu L
Lung Cancer; 2013 May; 80(2):131-7. PubMed ID: 23433592
[TBL] [Abstract][Full Text] [Related]
16. TRAF6 is an amplified oncogene bridging the RAS and NF-κB pathways in human lung cancer.
Starczynowski DT; Lockwood WW; Deléhouzée S; Chari R; Wegrzyn J; Fuller M; Tsao MS; Lam S; Gazdar AF; Lam WL; Karsan A
J Clin Invest; 2011 Oct; 121(10):4095-105. PubMed ID: 21911935
[TBL] [Abstract][Full Text] [Related]
17. Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer.
Takezawa K; Okamoto I; Nishio K; Jänne PA; Nakagawa K
Clin Cancer Res; 2011 Apr; 17(8):2140-8. PubMed ID: 21415216
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic ras-induced down-regulation of pro-apoptotic protease caspase-2 is required for malignant transformation of intestinal epithelial cells.
Yoo BH; Wang Y; Erdogan M; Sasazuki T; Shirasawa S; Corcos L; Sabapathy K; Rosen KV
J Biol Chem; 2011 Nov; 286(45):38894-903. PubMed ID: 21903589
[TBL] [Abstract][Full Text] [Related]
19. Protein kinase C δ is a downstream effector of oncogenic K-ras in lung tumors.
Symonds JM; Ohm AM; Carter CJ; Heasley LE; Boyle TA; Franklin WA; Reyland ME
Cancer Res; 2011 Mar; 71(6):2087-97. PubMed ID: 21335545
[TBL] [Abstract][Full Text] [Related]
20. Effect of disrupting seven-in-absentia homolog 2 function on lung cancer cell growth.
Ahmed AU; Schmidt RL; Park CH; Reed NR; Hesse SE; Thomas CF; Molina JR; Deschamps C; Yang P; Aubry MC; Tang AH
J Natl Cancer Inst; 2008 Nov; 100(22):1606-29. PubMed ID: 19001609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
